07:27 AM EDT, 08/28/2024 (MT Newswires) -- Revive Therapeutics ( RVVTF ) on Wednesday said a research study evaluating Bucillamine as a potential treatment for nerve agent exposure, is expected to be completed in October.

The study is being conducted in partnership with an agency of the Canadian Department of National Defence.

The results from the study, if promising, will determine further studies to facilitate U.S. FDA and Health Canada approvals for the use of Bucillamine in nerve agents, and explore its potential in viral infections, including monkeypox, Revive said.

Bucillamine has been prescribed as a treatment for rheumatoid arthritis in Japan and South Korea for over 30 years.